Drug Name	Indication Neurotransmitter(s) Affected Target Symptoms	Half-life (T1/2), Metabolism (CYP 450 enzyme)	Notable Side Effects (link to NT or affected brain circuit)	Initial Dosi Considerat Specific life considerati pregnancy,
Buprenorphine (Subutex)	**Indication:** • Maintenance treatment of opioid dependence • Maintenance treatment of opioid dependence in patients who have achieved and sustainced prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product • Moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days **Neurotransmitters:** • Mu opioid receptor partial agonist	**Half-life:** 24-42 hours **CYP450:** CYP3A4	• Headache, constipation, nausea • Oral hypoesthesia, glossodynia • Orthostatic hypotension • Implant specific: insertion site pain, pruritis, erythema • Respiratory depression • Hepatotoxicity	**Initial dosi** **Day 1:** 8 m **Day 2:** 12-1 **Days 3-7:** I increments maximum **Considerat** • Us in tho ca im • Ma pre me pre • Ne wit oc • Dr bre rec DO fee • Sa eff be for ad